glp-1 obesity drug news october 9 2025 2024 was a record year for trials and is already poised to take over Outlook for Obesity in 2026:

Trulicity has proven its effectiveness, convenience, and safety in clinical trials. Lilly Korea has remained ahead with its diabetes drug despite Novo Nordisk bringing some more challenging news abroad, industry watchers said

The Origins of GLP-1 Discovery and Early Research Scientists first identified GLP-1 as a natural hormone in the human intestine during the 1980s

Each incretin receptor agonist effects on body weight and energy metabolism may be slightly different and, in the case of dual and triple agonists, frequently complementary

It is a famously hard target for small-molecule agonism

10.1007/s11920-023-01458-0 [DOI] [PubMed] [Google Scholar] 14

These side effects are typically mild and you can take measures like getting fresh air, sipping cold drinks, and consuming smaller, more frequent meals to manage them